Daily Health Headlines

memantine, Namenda, Namenda XR

👤by AP 0 comments 🕔Tuesday, February 24th, 2015

DRUG CLASS AND MECHANISM: Memantine is an oral medication for treating patients with Alzheimer's disease. Other medications used for Alzheimer's disease affect acetylcholine, one of the neurotransmitter chemicals that nerve cells in the brain use to communicate with one another. These drugs - galantamine (Razadyne - formerly known as Reminyl), donezepil (Aricept), rivastigmine (Exelon), and tacrine (Cognex) - inhibit the enzyme acetylcholinesterase that destroys acetylcholine and thereby increase the effects of acetylcholine. Memantine's effects are independent of acetylcholine and acetylcholinesterase. Glutamate is the main excitatory neurotransmitter in the brain. It is believed that too much stimulation of nerve cells by glutamate may be responsible for the degeneration of nerves that occurs in some neurological diseases such as Alzheimer's disease. Like other neurotransmitters, glutamate is produced and released by nerve cells in the brain. The released glutamate then travels to nearby nerve cells where it attaches to a receptor on the surface of the cells called the N-methyl-D-aspartate (NMDA) receptor. Memantine blocks this receptor and thereby decreases the effects of glutamate. It is thought that by blocking the NMDA receptor and the effects of glutamate, memantine may protect nerve cells from excess stimulation by glutamate. Memantine was approved by the FDA in October 2003.

Medically Reviewed by a Doctor on 2/24/2015

memantine Index memantine on RxList

Report Problems to the Food and Drug Administration

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Need help identifying pills and medications?Use the pill identifier tool on RxList.

Back to Medications Index

Pharmacy Author:

Omudhome Ogbru, PharmD

Omudhome Ogbru, PharmD

Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.

Medical and Pharmacy Editor:

Jay W. Marks, MD

Jay W. Marks, MD

Jay W. Marks, MD, is a board-certified internist and gastroenterologist. He graduated from Yale University School of Medicine and trained in internal medicine and gastroenterology at UCLA/Cedars-Sinai Medical Center in Los Angeles.

Article Credits / Source

AP / MedicineNet.com

AP wrote this story for MedicineNet.com. MedicineNet.com provides up to the minute breaking health news. Click here to view this full article from MedicineNet.com.

View More Articles From AP 🌎View Article Website

Sponsored Product

Lunar Sleep for $1.95

Lunar Sleep for $1.95

People who have trouble sleeping typically have low levels of melatonin, so melatonin supplements seem like a logical fix for insomnia. There is a high demand for sleep aids, especially in the U.S. The National Health Interview Survey done in 2002, and again in 2007, found 1.6 million US adults were using complementary and alternative sleep aids for insomnia. Lunar Sleep was a top choice. Use Promo Code: Sleep2014 and only pay $1.95 S&H.

Get Lunar Sleep for $1.95

More Alzheimer's Disease Articles

Fewer Americans Suffering From Dementia, Study Finds

Fewer Americans Suffering From Dementia, Study Finds0

MONDAY, Nov. 21, 2016 (HealthDay News) -- Here's some good news for America's seniors: Dementia rates have dropped dramatically over the last decade or so, according to a new study. An analysis of responses from a study of more than 10,000 ...

Can Occupational Therapy Slow Alzheimer's Decline?

Can Occupational Therapy Slow Alzheimer's Decline?0

MONDAY, Nov. 21, 2016 (HealthDay News) -- Home-based occupational therapy may not slow down the physical decline that comes with Alzheimer's disease, a new clinical trial suggests. The study looked at whether home visits from occupational ...

Poor Sense of Smell May Signal Alzheimer's Risk

Poor Sense of Smell May Signal Alzheimer's Risk0

WEDNESDAY, Nov. 16, 2016 (HealthDay News) -- A person's sense of smell may help predict their risk for Alzheimer's disease, a new study suggests. The researchers included 183 older people, and 10 had possible or probable Alzheimer's disease, ...

Some Elderly With Alzheimer's Brain Plaques Stay Sharp

Some Elderly With Alzheimer's Brain Plaques Stay Sharp0

MONDAY, Nov. 14, 2016 (HealthDay News) -- In a discovery that challenges conventional thinking, researchers report that several people over the age of 90 had excellent memory even though their brains showed signs that they had Alzheimer's ...

Brain Scans May Improve Dementia Diagnosis, Treatment

Brain Scans May Improve Dementia Diagnosis, Treatment0

TUESDAY, Nov. 8, 2016 (HealthDay News) -- Tens of millions of people worldwide suffer from memory loss and mental impairment due to dementia. While there's no cure, medication may temporarily improve some symptoms. Proper treatment, however, depends ...

View More Alzheimer's Disease Articles


Write a Comment

Your email address will not be published. Required fields are marked *

Our Mailing List

Subscribe to our mailing list to get the latest health news as it breaks!

Your information will not be shared with anyone!